•  
• Tweet
•  
•        Print
•  
•         Track Keywords
•  
• 

Laxman Pai, Opalesque Asia:

London-based biotech venture capital firm 4Bio Capital has raised the first $50m for a new $150m fund to invest in "advanced therapies" such as gene and cell therapy.

Dmitry Kuzmin, the managing partner, said its 4Bio Ventures II fund had achieved its "first close" and expected to start investing next month. The full $150m will be reached next year.

The VC firm's fundraising follows a succession of funding announcements this summer in the UK and European life sciences sector, both for biotech companies and for funds. The fund will be focused solely on advanced therapies without geographic limit, giving investors access to the fastest-growing field of medicine, said a press note.

4BIO Ventures II will invest in 8 to 12 private companies developing advanced therapies - such as cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome - in areas of high unmet need.

The Group's objective is to build, support and grow early-stage companies with the ultimate goal of ensuring sustainable access to these potentially curative therapies for all patients.

Since 2010 the Group and its founders have participated in 29 biotech investments across the advanced therapies sector, and 4BIO's investment strategy has been validated by several recent exits including Orchard Therapeutics, Seres Therapeutics, and RetroSense Therapeutics, acquired by Allergan in 2016.

Dmitry Kuzmin said: "Advanced therapies are the fut......................

To view our full article Click here